BridgeBio Pharma (BBIO) Cash from Operations (2018 - 2026)

BridgeBio Pharma has reported Cash from Operations for 9 years, with the latest figure at 197279000.0 in Q1 2026.

• Quarterly Cash from Operations rose 0.98% year-over-year to 197279000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 443954000.0 (up 11.28% YoY) and the FY2025 annual result came in at 445910000.0, up 14.37% from the prior year.
• Cash from Operations eased to 197279000.0 in Q1 2026 per BBIO's latest filing, from 56420000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 74703000.0 in Q2 2024 and troughed at 219537000.0 in Q1 2024.
• A 5-year average of 124184058.82 and a median of 135163000.0 in 2022 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 272.22% in 2023, then soared 165.9% in 2024.
• Over 5 years, Cash from Operations stood at 93243000.0 in 2022, then slumped by 33.86% to 124819000.0 in 2023, then plunged by 56.49% to 195326000.0 in 2024, then soared by 71.11% to 56420000.0 in 2025, then tumbled by 249.66% to 197279000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 197279000.0, 56420000.0, and 109574000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.